KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Amortization of Deferred Charges (2016 - 2025)

Neogenomics (NEO) has disclosed Amortization of Deferred Charges for 15 consecutive years, with $9000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges fell 81.25% year-over-year to $9000.0, compared with a TTM value of $87000.0 through Dec 2025, down 53.97%, and an annual FY2025 reading of $87000.0, down 53.97% over the prior year.
  • Amortization of Deferred Charges was $9000.0 for Q4 2025 at Neogenomics, roughly flat from $9000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $48000.0 in Q4 2024 and bottomed at $9000.0 in Q3 2025.
  • Average Amortization of Deferred Charges over 5 years is $41050.0, with a median of $46000.0 recorded in 2022.
  • The sharpest move saw Amortization of Deferred Charges surged 73.08% in 2021, then tumbled 81.25% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $45000.0 in 2021, then rose by 2.22% to $46000.0 in 2022, then changed by 0.0% to $46000.0 in 2023, then increased by 4.35% to $48000.0 in 2024, then crashed by 81.25% to $9000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for NEO at $9000.0 in Q4 2025, $9000.0 in Q3 2025, and $21000.0 in Q2 2025.